Immune-related GFAP-Astrocytopathy under PD-1 inhibition: A case report

Read full text Summarise with VIRAT
Authors: Lea Daniello, Georgios Tassopoulos, Berenice Mareen Lang, Bastian Schilling
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immune checkpoint inhibitors have substantially improved survival in advanced melanoma but are also associated with immune-related adverse events. Such events can affect any organ, including the central and peripheral nervous systems. Neurological adverse events are rare and often underrecognized. We report the case of a 53-year-old woman with melanoma who developed a severe neurological adverse event after treatment with the PD-1 inhibitor nivolumab. We describe a rare case of nivolumab-associated glial fibrillary acidic protein astrocytopathy and highlight the diagnostic challenges, therapeutic considerations, and importance of early recognition of these potentially severe neurological adverse events.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Autoimmune Neurological Disorders and Treatments Glioma Diagnosis and Treatment

Publication details

Journal / source
EJC Skin Cancer
Volume
4
Pages
101136–101136
Publication date
1 January 2026
Language
EN